Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions

Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)Margin Assessment

Interventions

DRUG

Indocyanine Green (ICG)

Dose: 5 mg/kg IV injection prior to surgery

Trial Locations (1)

Medical University of South Carolina Hollings Cancer Center, Charleston

All Listed Sponsors

lead

Medical University of South Carolina

OTHER